Olema Pharmaceuticals (OLMA) late Tuesday reported Q4 net loss of $0.51 per diluted share, compared with $0.49 loss a year earlier.

The four analysts polled by FactSet, on average, expected a loss of $0.65.

The biopharmaceutical company recorded no revenue during the quarter ended Dec. 31, as expected.

Olema finished 2024 with around $434.1 million in cash and equivalents, up from $261.8 million at the end of 2023.